韩国医院员工接种第二剂BNT162b2 mRNA疫苗后12周内抗体应答的前瞻性纵向研究
该前瞻性纵向研究在韩国一家综合医院的71名医院员工中,于第二剂辉瑞/BioNTech BNT162b2 mRNA疫苗接种后第1至4周每周及第8、12周检测SARS-CoV-2抗受体结合域(抗RBD)抗体和中和抗体水平。结果显示初始中位抗RBD抗体为3898.0 U/mL(IQR 2107.5-5478.5),中和抗体为97.54%(IQR 96.85-97.81),第12周分别降至1163.0 U/mL(683.4-1743.0)和94.87%(89.24-96.99),抗体水平持续下降但12周时仍维持合理水平。
要点
- 第二剂BNT162b2接种后初始中位抗RBD抗体为3898.0 U/mL,中和抗体为97.54%。
- 抗体水平在第1至2周下降最快最显著(两者p<0.01),此后持续下降。
- 8周内88.7%(63/71)参与者抗RBD抗体降至初始水平一半以下。
核心结论
- 第二剂疫苗接种后产生相当高的SARS-CoV-2抗RBD和中和抗体水平,抗体水平持续下降呈随时间下降趋势,但至第12周仍维持合理水平。
- 考虑到疫苗接种后抗体应答的个体差异,需进一步进行个体间分析。
研究设计与样本
- 前瞻性纵向研究,纳入韩国一家综合医院的71名医院员工。
- 于第二剂辉瑞/BioNTech BNT162b2 mRNA疫苗接种后第1至4周每周及第8、12周检测SARS-CoV-2抗RBD抗体和中和抗体水平。
主要发现
- 初始中位抗RBD抗体为3898.0 U/mL(IQR 2107.5-5478.5),中和抗体为97.54%(IQR 96.85-97.81)。
- 抗体水平在第1至2周下降最快且最显著(两者p<0.01),此后持续下降,第12周抗RBD抗体为1163.0 U/mL(683.4-1743.0),中和抗体为94.87%(89.24-96.99)。
- 抗体水平在年龄较大组中随时间呈快速下降趋势。
- 8周内大多数参与者(88.7%:63/71)抗RBD抗体水平降至初始水平一半以下。
- SARS-CoV-2抗RBD抗体与中和抗体水平呈强正相关(Spearman相关系数=0.7833)。
局限性
- 考虑到疫苗接种后抗体应答的个体差异,需进一步进行个体间分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterise the antibody response for 12 weeks following second dose of the Pfizer/BioNTech BNT162b2 mRNA vaccine in hospital workers of a Korean general hospital. METHODS: We measured the level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-receptor binding domain (anti-RBD) and neutralising antibodies every week in the first 4 weeks, and at weeks 8 and 12 following the second dose of vaccination in 71 hospital workers. RESULTS: The initial median level of anti-RBD and neutralising antibodies were 3898.0 U/mL (interquartile range [IQR], 2107.5-5478.5) and 97.54 % (IQR, 96.85-97.81), respectively. The levels declined the fastest and the most significantly between weeks 1 and 2 (p < 0.01, both), and continuously decreased thereafter, and were 1163.0 U/mL (683.4-1743.0) and 94.87% (89.24-96.99) at weeks 12. The antibodies levels showed a trend of rapid decrease in the older group over time. The slope of the decrease in the antibodies level was observed for each individual. Within 8 weeks, the anti-RBD antibody levels decreased to less than half of the initial levels in most of the participants (88.7%: 63/71). The SARS-CoV-2 anti-RBD and neutralising antibodies levels showed a strong positive correlation (Spearman's coefficient = 0.7833). CONCLUSIONS: Considerably high levels of SARS-CoV-2 anti-RBD and neutralising antibodies were produced following the second dose of vaccination. The levels decreased continuously, showing a tendency to decline over time; however, reasonable levels persisted up to weeks 12. Moreover, considering individual variations in antibody response following vaccination, a further inter-individual analysis is needed.
引用
- Kim HJ, Yun HJ, Kim J, et al. Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study. Vaccine. 2021. PMID: 34953606. doi:10.1016/j.vaccine.2021.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。